Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050053/S068

INFUSE Bone Graft

Medtronic, Inc. · Decision date Mar 19, 2026

FDA DECISIONP050053/S068

What did the FDA decide?

FDA records P050053/S068 as a supplement to PMA P050053, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 19, 2026.

FDA approval order statement

addition of an alternate testing facility and relocation of relevant laboratories to a new building
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Dental
Decision date
Mar 19, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P050053/S068
Regulatory pathway
PMA supplement
Product code
NPZ
Decision code
OK30
Decision date
Mar 19, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Bone grafting material, dental, with biologic component.

Product code
NPZ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P050053/S068 received

    Application receipt date recorded by FDA.

  2. P050053/S068 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P050053. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050053

Product / regulatory recordCompanyPathwayDecision dateSource
INFUSE Bone GraftP050053/S067
Medtronic, Inc.PMA supplementFeb 24, 2026FDA
Infuse Bone GraftP050053/S069
Medtronic, Inc.PMA supplementJul 28, 2026FDA
INFUSE BONE GRAFTP050053/S066
Medtronic, Inc.PMA supplementAug 26, 2026FDA

Explore the linked device profile

Other records with product code NPZ

Product / regulatory recordCompanyPathwayDecision dateSource
Lynch Biologics, LLCPMA supplementAug 3, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
1800 Pyramid Pl., Memphis, TN, 38132

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records